Atrial Fibrillation
Atrial Fibrillation is a cardiovascular condition. It has been studied in people undergoing cardiac surgery or cardioversion, including research examining whether options such as Vitamin C or Magnesium may influence its occurrence in these settings.
Atrial Fibrillation is a cardiovascular condition. Start with a focused overview of where it fits in cardiovascular health.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
3 options:3 not enough evidence
High-Intensity Interval Training (HIIT)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
One randomized trial enrolled 86 adults with persistent or permanent atrial fibrillation.
Open the High-Intensity Interval Training (HIIT) pageMindfulness MeditationpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A pilot RCT involving 80 people undergoing RFCA found improvements in pain, anxiety, and fatigue during the procedure with BCI-based mindfulness meditation.
Open the Mindfulness Meditation pageHatha YogapracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A 2024 narrative review described studies reporting reduced atrial fibrillation burden and improved symptoms.
Open the Hatha Yoga page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition3 listedThe best we have, but the evidence is still weak
- →PracticesHigh-Intensity Interval Training (HIIT)CertaintyLowSourceClinical
One randomized trial enrolled 86 adults with persistent or permanent atrial fibrillation.
Who was studied
- People with a condition
- Atrial Fibrillation
Open High-Intensity Interval Training (HIIT)Study result
Study population of adults with persistent and permanent atrial fibrillation; the trial was conducted in this population.
- →PracticesMindfulness MeditationCertaintyLowSourceClinical
A pilot RCT involving 80 people undergoing RFCA found improvements in pain, anxiety, and fatigue during the procedure with BCI-based mindfulness meditation.
Who was studied
- People with a condition
Open Mindfulness MeditationStudy result
Pilot RCT showing improved pain, anxiety, fatigue during RFCA with BCI-based mindfulness meditation.
- →PracticesHatha YogaCertaintyLowSourceReview
A 2024 narrative review described studies reporting reduced atrial fibrillation burden and improved symptoms.
Open Hatha YogaStudy result
Multiple studies show reduced AF burden and improved symptoms.
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Atrial Fibrillation worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Atrial Fibrillation is a cardiovascular condition. It has been studied in people undergoing cardiac surgery or cardioversion, including research examining whether options such as Vitamin C or Magnesium may influence its occurrence in these settings.
Evidence-backed options
Vitamin C has been examined mainly in people undergoing cardiac surgery or cardioversion, rather than as a broadly established option for Atrial Fibrillation. Trials carried out in Iran and Greece indicated that it may help prevent AF in these settings, while trials involving cardiac surgery patients in the USA found no benefit. The differing findings across settings mean that the results do not establish a consistent effect for all people or circumstances.
Magnesium has been studied in clinical groups for prevention of new-onset atrial fibrillation after cardiac surgery. These studies did not find a reduction in NOAF, but they included diverse groups and were affected by significant bias, which limits how confidently the result can be interpreted.
The findings do not establish a consistent dose, treatment duration, or time to any possible effect for either option. Overall, the evidence is narrow and context-dependent, with important uncertainty about whether results from perioperative or cardioversion settings apply more broadly. These options are best understood as subjects of clinical evidence rather than established treatments; anyone considering them for a medical condition should discuss the relevant context with a clinician.
What to avoid
Prescription-strength Omega-3 requires particular caution in atrial fibrillation because doses around 4 g/day have been associated with increased atrial fibrillation or flutter events and recurrence. The absolute risk may be greater for people who have had atrial fibrillation previously, making high-dose use a matter for avoidance or close clinician supervision.
This concern is specific to prescription-strength, high-dose use and is not established for ordinary dietary doses. The distinction between high-dose preparations and dietary intake is therefore important when considering Omega-3 in the context of atrial fibrillation. Anyone with a medical condition should discuss its use with a clinician.